Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.
about
Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine releaseNicotinic receptor antagonists as treatments for nicotine abuse.Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers.Scientific overview: 2013 BBC plenary symposium on tobacco addiction.bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.Pharmacologically distinct nicotinic acetylcholine receptors drive efferent-mediated excitation in calyx-bearing vestibular afferentsRecent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior.Pharmacologic antagonism of ghrelin receptors attenuates development of nicotine induced locomotor sensitization in rats.Effects of nicotine administration on striatal dopamine signaling after traumatic brain injury in rats.r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.Functional interaction between pre-synaptic α6β2-containing nicotinic and adenosine A2A receptors in the control of dopamine release in the rat striatum.Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release.
P2860
Q33836376-7937610D-94DA-45C5-B903-1BABD7A5EB6EQ34401397-6CC35A51-A328-4025-B5A0-242F140B0141Q34458500-54F29A41-BB58-4B0F-8060-A8103A62380FQ34487271-65EB4D31-2487-4102-9204-77BE295ACE83Q34919642-706D0DC4-3289-4713-A51A-BDE25982D0FAQ35117646-37157ADB-AFA5-42CE-B3BA-2BB383A7C939Q35184641-6C3BFBD4-7631-4268-B595-2010A65A6AB0Q35394017-1A8655A1-0040-4F2E-A6A4-F9161D871A25Q35828300-CCA9FB71-D09C-4C22-82E5-15074C0EDE00Q36266312-1F601003-0C7B-4305-8E0F-7E0238F56F97Q37046788-6A38631B-DA7E-4F80-959C-931A2864D462Q40422963-3B91A1D0-BFD3-46EC-AE01-C9FB0299AC74
P2860
Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Repeated nicotine administrati ...... otine-evoked dopamine release.
@en
Repeated nicotine administrati ...... otine-evoked dopamine release.
@nl
type
label
Repeated nicotine administrati ...... otine-evoked dopamine release.
@en
Repeated nicotine administrati ...... otine-evoked dopamine release.
@nl
prefLabel
Repeated nicotine administrati ...... otine-evoked dopamine release.
@en
Repeated nicotine administrati ...... otine-evoked dopamine release.
@nl
P2093
P2860
P1476
Repeated nicotine administrati ...... otine-evoked dopamine release.
@en
P2093
Andrew M Smith
Guangrong Zheng
J Michael McIntosh
Linda P Dwoskin
Marharyta Pivavarchyk
Michael T Bardo
Peter A Crooks
Thomas E Wooters
Zhenfa Zhang
P2860
P304
P356
10.1016/J.BCP.2010.03.018
P407
P577
2010-03-25T00:00:00Z